Related Experiment Video

Updated: Feb 1, 2026

Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis
04:05

Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis

Published on: June 30, 2023

2.9K

Canrenone on cardiovascular mortality in congestive heart failure: CanrenOne eFFects on cardiovascular mortality in

Giuseppe Derosa1, Pamela Maffioli2, Laura Scelsi3

  • 1Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy; Diabetes, Metabolic Diseases, and Dyslipidemia Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

Pharmacological Research
|December 4, 2018
PubMed

Insights

Canrenone therapy in patients with chronic heart failure (CHF) and preserved ejection fraction significantly reduced cardiovascular mortality and extended survival over a 10-year period compared to conventional treatments.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Chronic heart failure (CHF) with preserved systolic function affects a significant patient population.
  • Optimal therapeutic strategies for CHF with preserved systolic function remain an area of active research.

Purpose of the Study:

  • To evaluate the long-term effects of canrenone compared to conventional therapies on cardiovascular mortality in patients with CHF and preserved systolic function.

Main Methods:

  • A cohort of 532 patients with CHF and preserved systolic function was followed for a mean of 10 years.
  • Patients received either canrenone (n=166) or conventional therapy (n=336).
  • Outcomes assessed included mortality, survival rates, and various clinical and biochemical markers.

Main Results:

  • Canrenone treatment was associated with lower systolic and diastolic blood pressure, reduced fasting plasma glucose and glycated hemoglobin, and lower aldosterone levels.
  • After 10 years, the canrenone group exhibited lower left ventricular mass and a slower progression of NYHA class.
  • Importantly, patients treated with canrenone demonstrated longer survival and a reduced number of deaths compared to the control group.

Conclusions:

  • Canrenone administration in patients with CHF and preserved systolic function effectively reduced mortality and prolonged survival.
  • These findings suggest canrenone as a beneficial therapeutic option for this patient cohort.
Abstract

Keywords:
CanrenoneCongestive heart failureLong-Term mortalitySurvival

More Related Videos

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.0K
Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.2K

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
933
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.7K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
888
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
339
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
968
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
316